Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology

Actualizado 26/06/2007 17:14:27 CET


-- ABT-751, an oral anti-mitotic in Phase II studies for non-small cell
lung cancer and neuroblastoma;
-- ABT-888, a PARP inhibitor that can prevent DNA damage repair in cancer
cells, and thereby enhance the effectiveness of current cancer
therapies;
-- ABT-828, a biologic anti-tumor agent with a novel mechanism of action.

These compounds are not part of the collaboration with Genentech.

About Genentech

Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, California and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

[TAB]

Web site: http://www.abbott.com

http://www.gene.com

[FTAB]

media, Catherine Bryan, +1-847-936-6722, or financial, John Thomas, +1-847-938-2655, both of Abbott; or Media Relations, Caroline Pecquet, +1-650-467-7078, or Investor Relations, Kathee Littrell, +1-650-225-1034, both of Genentec

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación